Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented. by Rathod, Sujit D & Buffler, Patricia A
Rathod, SD; Buﬄer, PA (2014) Highly-cited estimates of the cumu-
lative incidence and recurrence of vulvovaginal candidiasis are inad-
equately documented. BMC Womens Health, 14 (1). p. 43. ISSN
1472-6874 DOI: 10.1186/1472-6874-14-43
Downloaded from: http://researchonline.lshtm.ac.uk/1620849/
DOI: 10.1186/1472-6874-14-43
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
DEBATE Open Access
Highly-cited estimates of the cumulative incidence
and recurrence of vulvovaginal candidiasis are
inadequately documented
Sujit D Rathod1,2*† and Patricia A Buffler1†
Abstract
Background: Available literature concerning the epidemiologic or clinical features of vulvovaginal candidiasis
commonly reports that: 75% of women will experience an episode of vulvovaginal candidiasis in their lifetimes, 50%
of whom will experience at least a second episode, and 5-10% of all women will experience recurrent vulvovaginal
candidiasis (≥4 episodes/1 year). In this debate we traced the three commonly cited statistics to their presumed origins.
Discussion: It is apparent that these figures were inadequately documented and lacked supporting epidemiologic
evidence. Population-based studies are needed to make reliable estimates of the lifetime risk of vulvovaginal candidiasis
and the proportion of women who experience recurrent candidiasis.
Summary: The extent to which vulvovaginal candidiasis is a source of population-level morbidity remains uncertain.
Background
Vulvovaginal candidiasis is a commonly reported gyne-
cological condition and is diagnosed in a large proportion
of women presenting to medical facilities with a complaint
of abnormal vaginal discharge [1]. While not a cause of
mortality, the morbidity associated with vulvovaginal
candidiasis make it a major cause of mental distress [2]
and economic costs [3]. Though there are well-recognized
limitations of the existing epidemiologic data for vulvo-
vaginal candidiasis [4], frequently-cited incidence and
recurrence figures reported in the vulvovaginal candidiasis
literature are not, in fact, supported by published epide-
miologic studies. Specifically, the literature describing the
epidemiologic and clinical features of vulvovaginal candid-
iasis commonly reports that approximately:
 75% of women will experience an episode of
vulvovaginal candidiasis in their lifetimes [5-56],
 50% of initially infected women will experience at least
a second episode [5,6,8,10,11,13-15,18,20,22-25,27,
29-33,36-40,44,46,50,51,53], and
 5-10% of all women experience recurrent vulvovaginal
candidiasis (RVVC) (≥4 episodes/1 year) [6,9,11,16,
18,21,23-26,28,29,31-34,39,43-45,48,51-53,57-62].
An investigation into the sources of these statistics
suggests that these commonly reported figures ultimately
represent restatements of information derived from
unpublished reports and clinical opinion. The regular
reference to these undocumented estimates in the litera-
ture has developed an “unfounded authority”, which
masks the need for further study of the epidemiologic
features of vulvovaginal candidiasis.
Discussion
While searching for the primary studies that would provide
the epidemiologic support for these statistics, we noted
that a number of articles in gynecology journals either
directly, or indirectly via intermediary articles, refer to
the work of Hurley, with the assertion that, “75% of
women will experience an episode of vulvovaginal can-
didiasis in their lifetimes.” In 1977, Hurley provided a
historical overview of Candida vaginitis at a meeting of
experts from the United Kingdom and Belgium [63].
Hurley referred to work by Ajello, stating that “the true
incidence and prevalence of mycotic disease remains
unknown” [64]. In a later publication, Hurley and de
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Louvois reported that “It is likely that between 1/20
to 1/7 of women of child-bearing years suffer from
Candida vaginitis” [65]. It is clear from reading Hurley’s
cited work that she did not purport to estimate the
lifetime incidence of vulvovaginal candidiasis, yet her
publications are frequently cited by others to support
the 75% figure.
With regard to the estimate of repeat episodes of vul-
vovaginal candidiasis experienced by women, Hurley is
again directly or indirectly cited by others to support the
assertion that: “50% of those women will experience at
least a second episode [of vulvovaginal candidiasis].” Our
search for the source of this estimate indicates that the
likely source is a presumably unpublished study Hurley
describes in a paper published in 1977: “A retrospective
survey of some 500 women treated for pregnancy thrush
showed that 45% had had more than one course of treat-
ment during pregnancy” [63]. Hurley does not provide a
reference for this study. Hurley refers to similar results
from “unpublished observations” in a paper published in
1975: "A retrospective survey (Hurley and Stanley, 1973)
showed that more than half of 300 women treated for
pregnancy thrush had had two or more courses of ther-
apy” [2]. The studies to which Hurley refers concern
treatment failure – i.e. not of multiple, distinct episodes
of vulvovaginal candidiasis - in women during pregnancy,
and apparently these estimates were never published in
the peer-reviewed literature. Thus, the citations attributed
to Hurley do not provide adequate documentation for the
50% recurrence estimate.
There also does not appear to be adequate support for
the statement: “5-10% of all women experience recurrent
vulvovaginal candidiasis.” The earliest reference to this
estimate was traced to Sobel, who in 1993 stated that:
“A small subpopulation of undetermined size, probably less
than 5% of adult women, has recurrent, often intractable,
episodes of this disorder” [18]. The previous year Sobel
specifically stated “There are no accurate figures describing
the magnitude of the group with recurrent infection”, which
he found was still the case in 2003 “The true incidence
of RVVC remains unknown” [66,67]. Though there is
ample anecdotal evidence that many women suffer from
recurrent vulvovaginal candidiasis, Sobel’s publications do
not purport to definitively estimate the proportion of
the population comprised of these women. Since Sobel’s
estimate was published there have been two population-
based studies of the prevalence of recurrent vulvovaginal
candidiasis, both of which found that approximately 8% of
women are affected by RVVC [3,68]. These studies –
though the most rigorous available – must be interpreted
with caution, as few of the women recruited opted to
participate, there was evidence that recall of past diagno-
ses diminished over time, and the criteria the participants’
physicians used to make the diagnoses were unknown.
Though a co-author on these studies, Sobel himself has
remarked that the use of self-reported recall of physician
diagnoses “multiplies errors”, and that other studies are
subject to selection bias in the form of women self-
selecting to become patients [4].
A limiting characteristic of other studies cited with
regard to the cumulative incidence of vulvovaginal candid-
iasis is the use of self-reported history of vulvovaginal
candidiasis [3,13,68-72]. For example, Berg noted that
72% of 204 adult women visiting a medical center in
the United States reported a history of yeast infections
[69]. Yet, few authors subsequently citing Berg note the
self-reported nature of these data. In their review of
genital candidiasis, Achkar and Fries found only two
population-based studies of the incidence of vulvovaginal
candidiasis, both of which relied on self-reported diagno-
ses [5]. In the absence of laboratory-confirmation of Can-
dida in women with vulvovaginal candidiasis-associated
symptoms, both self-diagnosis and clinical diagnosis are
known to be of low accuracy [4,73-76].
Accordingly, diagnostic guidelines from the US Centers
of Disease Control recommend use of wet mount, culture
or other laboratory tests to confirm the presence of
vaginal Candida among women reporting symptoms
consistent with vulvovaginal candidiasis [51]. Conversely,
population-based studies which only measure vaginal
colonization by Candida without clinical examination
cannot confirm diagnoses of symptomatic vulvovaginal
candidiasis [74]. While it is valuable to understand the
incidence of vaginitis, and of vaginal carriage of Candida,
neither alone is sufficient to estimate the cumulative inci-
dence or recurrence of vulvovaginal candidiasis.
The peer-reviewed literature on vulvovaginal candidiasis
continues to report these unsupported estimates for the
incidence and recurrence among all women. One may
posit that over time these estimates have fostered an
impression among clinicians that women with vaginitis
have a high probability of having vulvovaginal candidiasis,
so much so that many clinicians dispense with confirma-
tory tests and rely on syndromic diagnoses. Then, in the
words of Sobel: “Misdiagnosis by clinicians inevitably re-
sults in incorrect self-diagnosis by patients” [4] – a finding
which has been confirmed [77]. These misdiagnoses will
continue to manifest themselves in research data which
rely on self-reported recall of self- or physician-diagnosed
vulvovaginal candidiasis.
Researchers who publish reports concerning vulvovagi-
nal candidiasis continue to cite the publications of Hurley
and Sobel. Based on our inquiry into the origins of these
estimates in the vulvovaginal candidiasis literature, it
appears that these inadequately documented estimates
have acquired an “unfounded authority” via repeated
citation in the peer-reviewed literature, a phenomena
described by Greenberg [78].
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Population-based cohort studies are essential for provid-
ing reasonable estimates of the incidence and recurrence
of vulvovaginal candidiasis. A study of this nature requires:
1) a population-based survey of women to identify preva-
lent infections; 2) prospective follow-up of an initially
unaffected cohort for at least one year; 3) laboratory
testing for the presence of Candida species upon report of
vulvovaginal candidiasis-associated symptoms; and 4)
exclusion of Candida as an “innocent bystander” (i.e. when
symptoms are a consequence of another condition) [4].
Absent data derived in this manner, it is not possible to
make reliable estimates of the incidence and recurrence of
vulvovaginal candidiasis in a population.
Summary
To obtain resources needed for the investigation of a non-
lethal health condition, public health researchers must
demonstrate that the condition represents a substantial
burden on a population level. In the case of vulvovaginal
candidiasis, this is contingent on vulvovaginal candidiasis
having an unacceptably high incidence and recurrence.
As described above, the commonly cited incidence and
recurrence figures were not derived from empiric investiga-
tion. Thus, the extent to which vulvovaginal candidiasis is a
source of population-level morbidity remains uncertain.
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